Luye Pharma Group announced today that the enrollment and follow-up of patients in a phase III clinical trial, an efficacy and safety comparative study of LY03005 with placebo, has been completed in r...
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Transdermal Patch, has been approved by the National Medical Products Administration in China....
-Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines- Two companies pledge to make joint effort to raise awareness of mental hea...
Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate releas...
Shanghai, September 11, 2020–The Shanghai Mental Health Center (SMHC) and Mindfront Health, a subsidiary of Luye Life Sciences Group, entered into a strategic partnership today. The two parties ...
Luye Pharma Group announced today that the company has received the approval from the Center for Drug Evaluation of China to begin clinical trials for the new drug product Rivastigmine Multi-Day Trans...
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Transdermal Patch, has been approved by the National Medical Products Administration in China....
Luye Pharma Group’s partner PharmaMar announced that its innovative anticancer drug, Lurbinectedin, has been added to the National Comprehensive Cancer Network’s (NCCN®) Clinical Practice ...
Luye Pharma Group today announced that it has entered into an exclusive promotion agreement with Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda. and Moksha8 Farmac&eac...
Luye Pharma Group is accelerating its biopharmaceutical pipeline globally. Shandong Boan Biological Technology Co. Ltd, the holding subsidiary of Luye Pharma Group, has recently submitted the investig...
TOP